13 research outputs found
PIN22 Economic Impact of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Persons Over 50 Years of Age With Underlying Chronic Medical Conditions in Finland
Get PDFPMS81 Cost-Effectiveness and Budget Impact of Certolizumab Pegol Against a Mix of Treatments in an Outcomes-Based Risk-Sharing Scheme in Finland
Get PDFCost-Effectiveness of Sequences of Biologic Treatments for Moderate-To-Severe Psoriasis in Finland
No full textPMS81 Cost-Effectiveness and Budget Impact of Certolizumab Pegol Against a Mix of Treatments in an Outcomes-Based Risk-Sharing Scheme in Finland
No full textCost-Utility of First-Line Adalimumab and Tocilizumab Monotherapies in Rheumatoid Arthritis Based on Head-To-Head Data
No full textVI3 Sequential Treatment of Follicular Non-Hodgkin Lymphoma: Cost-Effectiveness and Value of information
No full textCurrent and Future Strategy for Osteoporosis Screening and Diagnostics: Cost-Effectiveness of Frax with or without Pulse-Echo Ultrasound Measurement of Bone Mineral Density and DXA on Demand
No full textPIN22 Economic Impact of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Persons Over 50 Years of Age With Underlying Chronic Medical Conditions in Finland
No full textPMH68 Differential Use of Extended and Instant Release Quetiapine: A Naturalistic Study of Finnish Inpatients with Schizophrenia Spectrum or Bipolar Disorders
No full textCost-Utility of Vortioxetine in the Treatment of Major Depressive Disorder: Comparison with Agomelatine, Bupropion, Sertraline and Venlafaxine in the Finnish Setting
No full text
